Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Eukaryotic Transcription Inhibitors

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Attempts to Achieve Targeted Covalent Inhibition of Hsp90β.

Chemical biology & drug design·2026

Same author

Cell-Impermeable Hsp90α-Selective Inhibitor NDNA4 Inhibits Cancer Cell Migration and Targets Extracellular Hsp90α's Critical F-5 Fragment.

ACS chemical biology·2026

Same author

Synergistic Disruption of Survival and Metastatic Potential in Esophageal Adenocarcinoma Cells Through Combined Inhibition of HIF1α and CD73.

Cancers·2025

Same author

Optimization of Hsp90/Aha1 Small-Molecule Disruptors Via the Evaluation of Amide Bioisosteres.

ACS medicinal chemistry letters·2025

Same author

Hsp90β-Selective Inhibitors: Probing the Solvent-Accessible Frontier.

ChemMedChem·2025

Same author

Integrative Multi-Omics Analyses Reveal Mechanisms of Resistance to Hsp90β-Selective Inhibition.

Cancers·2025

Search research articles

Related Experiment Video

Updated: Jun 1, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

Conformationally Restricted Grp94-Selective Inhibitors.

Hao Xu¹, Kyler Pugh¹, Brian S J Blagg¹

¹Department of Chemistry and Biochemistry, Warren Center for Drug Discovery, The University of Notre Dame, 305 McCourtney Hall, Notre Dame, Indiana 46556, United States.

|January 20, 2025

Summary

Researchers developed new Grp94 inhibitors by modifying KUNG65. Lead compound C6 selectively binds Grp94, showing promise for treating diseases like cancer and glaucoma.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jun 1, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Area of Science:

Biochemistry
Medicinal Chemistry
Molecular Biology

Background:

Glucose-regulated protein 94 (Grp94) is a unique heat shock protein 90 (Hsp90) isoform.
Selective Grp94 inhibition is a therapeutic strategy for primary open-angle glaucoma and metastatic cancer.

Purpose of the Study:

To design and synthesize novel Grp94-selective inhibitors by conformationally restricting the KUNG65 scaffold.
To improve binding affinity and selectivity for Grp94 over other Hsp90 isoforms.

Main Methods:

Conformational restriction of nine KUNG65 analogues to bias benzyl moiety into Grp94 site 1 pocket.
Synthesis of analogues to reduce entropic penalty upon binding.
Fluorescence polarization assay to determine binding affinity and selectivity.

Main Results:

Lead compound C6 demonstrated a Grp94 affinity of 5.52 μM.
Compound C6 exhibited no significant affinity for Hsp90α.
The conformational constraints successfully biased the benzyl moiety into the Grp94 site 1 pocket.

Conclusions:

Compound C6 represents a potent and selective Grp94 inhibitor.
The developed analogues show therapeutic potential for Grp94-related diseases.
Conformational restriction is an effective strategy for designing selective Hsp90 isoform inhibitors.